ESR1 and breast carcinoma: Elbaz et al found that activation of CB2 with a CB2‐specific agonist (JWH‐015) inhibited EGF and IGF‐1 mediated invasion and migration in both estrogen receptor‐positive and‐negative breast cancer cells.52